Alessandra Fabi1, Diana Giannarelli2, Luca Moscetti3, Daniele Santini4, Alberto Zambelli5, Michelino De Laurentiis6, Michele Caruso7, Daniele Generali8, Enrichetta Valle9, Vita Leonardi10, Katia Cannita11, Grazia Arpino12, Gianfranco Filippelli13, Gianluigi Ferretti1, Marianna Giampaglia14, Filippo Montemurro15, Cecilia Nisticò1, Simona Gasparro1, Francesco Cognetti1. 1. Oncologia Medica 1, Istituto Nazionale Tumori 'Regina Elena', Roma, 00144, Italy. 2. Unità di Biostatistica, Istituto Nazionale Tumori 'Regina Elena', Roma, 00144, Italy. 3. Oncologia Medica, Ospedale Modena, Modena, 41125, Italy. 4. Oncologia Medica, Campus Bio-medico Universitario, Roma, 00128, Italy. 5. Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, 24127, Italy. 6. Breast Unit, Istituto Pascale, Napoli, 80131, Italy. 7. Humanitas Centro Catanese di Oncologia, Catania, 95126, Italy. 8. Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, 34127, Trieste, Italy. 9. Oncologia Medica, Ospedale Businco, Cagliari, 09121, Italy. 10. Oncologia Medica, ARNAS Civico, Palermo, 90127 Italy. 11. Oncologia Medica Ospedale L'Aquila, L'Aquila, 67100, Italy. 12. Oncologia Medica, Università Federico II, Napoli, 80138, Italy. 13. Oncologia PO di Paola, ASP di Cosenza, Cosenza, Italy. 14. Oncologia Medica, Ospedale San Carlo, Potenza, 85100, Italy. 15. Fondazione del Piemonte per l'Oncologia, Istituto Tumori Candiolo, Torino, 10060, Italy.
Abstract
AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen. PATIENTS & METHODS: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73). RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01). CONCLUSION: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.
AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen. PATIENTS & METHODS:Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73). RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01). CONCLUSION:Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.
Entities:
Keywords:
HER2 second-line; HER2-positive tumors; T-DM1; metastatic breast cancer; pertuzumab
Authors: Virginia F Borges; Cristiano Ferrario; Nathalie Aucoin; Carla Falkson; Qamar Khan; Ian Krop; Stephen Welch; Alison Conlin; Jorge Chaves; Philippe L Bedard; Marc Chamberlain; Todd Gray; Alex Vo; Erika Hamilton Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Nandini Dey; Jennifer Aske; Xiaoqian Lin; Yuliang Sun; Brian Leyland-Jones; Lori Friedman; Pradip De Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166
Authors: Salvatore Del Prete; Liliana Montella; Grazia Arpino; Giuseppe Buono; Carlo Buonerba; Pasquale Dolce; Olga Fiorentino; Maria Aliberti; Antonio Febbraro; Clementina Savastano; Giuseppe Colantuoni; Ferdinando Riccardi; Angela Ruggiero; Sabino De Placido; Michele Orditura Journal: Oncotarget Date: 2020-06-02